We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 15 for:    Phase 1 Clinical Trial of Autologous GD2
Previous Study | Return to List | Next Study

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04196413
Recruitment Status : Recruiting
First Posted : December 12, 2019
Last Update Posted : June 24, 2022
Information provided by (Responsible Party):
Crystal Mackall, MD, Stanford University

Brief Summary:
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.

Condition or disease Intervention/treatment Phase
Glioma of Spinal Cord Glioma of Brainstem Drug: GD2 CAR T cells Drug: Fludarabine Drug: Cyclophosphamide Phase 1

Detailed Description:

Primary Objectives:

  • Determine the feasibility of manufacturing autologous T cells transduced with 14g2a-CD8-BBz-iCasp9 retroviral vector expressing GD2 Chimeric Antigen Receptor (GD2CART) for administration in subjects with H3K27M+ diffuse intrinsic pontine glioma (DIPG) or subjects with spinal H3 K27M-mutant diffuse midline glioma (DMG) using a retroviral vector and dasatinib in the Miltenyi CliniMACS Prodigy® system.
  • Assess the safety and identify the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of GD2CART in subjects with H3K27M+ DIPG administered after cyclophosphamide/fludarabine-based lymphodepletion regimen using the following dose escalation schedule: DL1: 1e6 transduced T cells/kg; DL2: 3e6 transduced T cells/kg; DL3: 10e6 transduced T cells/kg.
  • Assess the safety of the MTD/RP2D of GD2CART in subjects with spinal H3K27M mutant DMG.

Secondary Objectives:

  • In a preliminary manner, assess clinical benefit of GD2CART at the RP2D in subjects with H3K27M DIPG or spinal H3 K27M-mutant DMG.
  • If unacceptable toxicity occurs that is possibly, probably or likely related to GD2CART, assess the capacity for AP1903, a dimerizing agent, to mediate clearance of the genetically engineered cells and resolve toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
Actual Study Start Date : June 4, 2020
Estimated Primary Completion Date : July 31, 2027
Estimated Study Completion Date : July 31, 2042

Arm Intervention/treatment
Experimental: GD2-CAR T

Dose escalation in subjects with DIPG:

A standard 3+3 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG, starting with Dose

Level 1:

  • Dose Level 1: 1x10^6 CAR+ T cells/kg body weight (+/- 20%)
  • Dose Level 2: 3x10^6 CAR+ T cells/kg body weight (+/- 20%)
  • Dose Level 3: 10x10^6 CAR+ T cells/kg body weight (+/- 20%)

Dose Level -1 will be explored if the first subject treated experiences dose limiting toxicity (DLT) or if >2 of 6 subjects treated at Dose Level 1 experiences DLT.

Dose expansion in subjects with DIPG and spinal DMG: Once the MTD or RP2D is determined, up to 20 evaluable subjects with H3K27M-mutant DIPG and 10 evaluable subjects with H3K27M-mutant spinal DMG will be treated at the RP2D (including subjects treated during dose escalation).

Drug: GD2 CAR T cells
Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Drug: Fludarabine
Fludarabine 25 mg/m2 per day IV for days -4, -3, -2

Drug: Cyclophosphamide
Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2

Primary Outcome Measures :
  1. Rate of successful manufacture of GD2CART using a retroviral vector in the Miltenyi CliniMACS Prodigy system [ Time Frame: 14 days after apheresis ]
    The percentage of apheresis samples (fresh or frozen) will be determined for each dose cohort.

  2. Maximum tolerated dose (MTD)/RP2D of GD2CART in subjects with H3K27M DIPG [ Time Frame: 28 days after infusion ]
    Severity of dose limiting toxicities (DLTs) following chemotherapy and infusion of GD2CART cells, will be recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at each dose level tested in subjects with H3K27M-mutant DIPG following standard upfront radiation therapy.

  3. Safety of GD2CART in subjects with spinal H3 K27M-mutant DMG treated at the RP2D [ Time Frame: 28 days after infusion ]
    Severity of dose limiting toxicities (DLTs) following chemotherapy and infusion of GD2CART cells will be recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in subjects with spinal H3K27M-mutant DMG following standard upfront radiation therapy

Secondary Outcome Measures :
  1. Radiographic Response Rate [ Time Frame: Time Frame: Day 28, 3 months, 6 months, 9 months and 12 months and 24 months post CAR T cell infusion. ]

    Radiographic Response will be evaluated using tumor response criteria:

    Complete Response (CR): disappearance on MR of all evaluable tumor and mass effect; stable or improving neurologic examination. If CSF was positive, it must be negative.

    Partial Response (PR): ≥ to 50% reduction in tumor size; stable or improving neurologic examination.

    Stable Disease (SD): at least stable and maintenance corticosteroid dose not increased, and MR/CT imaging meets neither PR nor PD Progressive Disease (PD): Progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression; OR a > 25% increase in the bi-dimensional measurement, OR the appearance of a new tumor lesion.

  2. Overall Survival (OS) [ Time Frame: Time Frame: Day 28, 3 months, 6 months, 9 months and 12 months and 24 months post CAR T cell infusion. ]
    OS is defined as the time from the start of the lymphodepleting chemotherapy preparative regimen to the date of death from any cause

  3. Progression-Free Survival (PFS) [ Time Frame: Time Frame: Day 28, 3 months, 6 months, 9 months and 12 months and 24 months post CAR T cell infusion ]
    PFS is defined as the time from the start of the lymphodepleting chemotherapy preparative regimen to the date of radiographic progression or death from any cause.

  4. Post-progression survival (PPS) [ Time Frame: ime Frame: Day 28, 3 months, 6 months, 9 months and 12 months and 24 months post CAR T cell infusion ]
    PPS is measured for each subject with DIPG as OS minus PFS, and for each patient with recorded progression as OS minus Time to Progression (TTP)

  5. Measure resolution of toxicity [ Time Frame: 72 hours of administration of AP1903 ]
    Resolution of toxicity ≤ grade2, in the event unacceptable toxicity considered possibly, probably or definitely related to GD2CART cells within 72 hours

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

International patients are not currently eligible to enroll.

Inclusion Criteria:

  • Currently accepting US patients only
  • Disease Status:
  • Tissue diagnosis of H3K27M-mutated Diffuse Intrinsic Pontine Glioma (DIPG) with radiographically evident tumor restricted to the brainstem, OR
  • Tissue diagnosis of H3K27M-mutated Diffuse Midline Glioma (DMG) of the spinal cord
  • Age: Greater than or equal to 2 year of age and less than or equal to 30 years of age

Prior Therapy:

  • At least 6 weeks following completion of front line radiation therapy.
  • At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives.
  • Performance Status: Subjects > 16 years of age: Karnofsky ≥ 60% OR Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Subjects ≤ 16 years of age: Lansky scale ≥ 60%
  • Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion)

    1. Absolute neutrophil count (ANC) ≥ 1,000/uL
    2. Platelet count ≥ 100,000/uL
    3. Absolute lymphocyte count ≥ 150/uL
    4. Hemoglobin ≥ 8 g/dL
    5. Adequate renal, hepatic, pulmonary and cardiac function defined as:

      • Creatinine within institutional norms for age (i.e. ≤ 2 mg/dL in adults or according to table below in children <18 years) OR creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min
      • Age (Years) -- Maximum Serum Creatinine (mg/dL)
      • ≤5 Years ---------------- 0.8mg/dL
      • 5 < age ≤ 10 Years ----1.0mg/dL
      • >10-18 Years -----------1.2mg/dL
      • >18 Years -----------2.0mg/dL
      • Serum Alanine aminotransferase( ALT)/Aspartate Aminotransferase (AST) ≤ 3.0 Upper limit of normal (ULN )(grade 1)
      • Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.
      • Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant ECG findings
      • Baseline oxygen saturation > 92% on room air
  • Pregnancy Test Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization are not considered to be of childbearing potential).
  • Contraception Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative lymphodepletion regimen or for as long as GD2-CAR T cells are detectable in peripheral blood or cerebrospinal fluid (CSF).
  • Ability to give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriate.

Exclusion Criteria:

  • Tumor involvement of cerebellar vermis or hemispheres (pontocerebellar peduncle involvement is allowed), thalamic lesions, or supratentorial lesions.
  • Clinically significant swallowing dysfunction.
  • Current systemic corticosteroid therapy
  • Prior CAR therapy.
  • Uncontrolled fungal, bacterial, viral, or other infection. Previously diagnosed infection for which the patient continues to receive antimicrobial therapy is permitted if responding to treatment and clinically stable.
  • Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti Hepatitis C Virus (HCV) positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chan reaction (PCR) and/or nucleic acid testing.
  • Clinically significant systemic illness or medical condition (e.g. significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgement of the principal investigator is likely to interfere with assessment of safety or efficacy of the investigational regimen and its requirements.
  • In the investigator's judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation.
  • Known sensitivity or allergy to any agents/reagents used in this study.
  • Primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04196413

Layout table for location contacts
Contact: Ashley Jacobs, RN, BSN 650-497-7533 gd2cart@stanfordchildrens.org

Layout table for location information
United States, California
Lucile Packard Children's Hospital (LPCH) Recruiting
Stanford, California, United States, 94304
Contact: Ashley Jacobs    650-497-7533    GD2CART@stanfordchildrens.org   
Principal Investigator: Michelle Monje, MD, PHD         
Sub-Investigator: Liora Schultz, MD         
Sub-Investigator: Kara Davis, D.O.         
Sub-Investigator: Robbie Majzner, MD         
Sub-Investigator: Crystal Mackall, MD         
Sub-Investigator: Gerald Grant, M.D., FACS         
Sub-Investigator: Sneha Ramakrishna, MD         
Sub-Investigator: Cynthia Campen, MD         
Sub-Investigator: Sonia Partap, MD         
Sub-Investigator: Paul Fisher, MD         
Sub-Investigator: Lindsey Rasmussen, MD         
Sub-Investigator: Timothy Cornell, MD         
Sub-Investigator: Susan Hinicker, MD         
Sub-Investigator: Vali Barstan, MD         
Sub-Investigator: Rebecca Richards, MD         
Sub-Investigator: Kristen Yeom, MD         
Sponsors and Collaborators
Crystal Mackall, MD
Layout table for investigator information
Principal Investigator: Michelle Monje Stanford University
Layout table for additonal information
Responsible Party: Crystal Mackall, MD, Professor of Pediatrics and of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT04196413    
Other Study ID Numbers: IRB-52934
PEDSCCT6005 ( Other Identifier: OnCore )
First Posted: December 12, 2019    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diffuse Intrinsic Pontine Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Brain Stem Neoplasms
Infratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists